Tumor microenvironment for cancer stem cells

Advanced Drug Delivery Reviews

Volumn 99, Issue , 2016, Pages 197-205

  Kise, Kazuyoshi ^a   Kinugasa Katayama, Yumi ^a,b   Takakura, Nobuyuki ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Cancer stem cells; Endothelial cells; Macrophages; Myofibroblasts; Niche; Tumor microenvironment

Indexed keywords

CELL CULTURE; CYTOLOGY; DISEASES; DRUG THERAPY; ENDOTHELIAL CELLS; FIBROBLASTS; MACROPHAGES; STEM CELLS; TISSUE; TUMORS;

ANTI-CANCER THERAPIES; CANCER STEM CELLS; MICROENVIRONMENTS; MOLECULAR MECHANISM; MYOFIBROBLASTS; NICHE; TISSUE SPECIFICS; TUMOR MICROENVIRONMENT;

CELLS;

BREAST CANCER; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL MATURATION; COLON CANCER; ENDOTHELIUM CELL; FIBROBLAST; GLIOBLASTOMA; IMMUNOCOMPETENT CELL; LEUKEMIA; MACROPHAGE; MESENCHYME CELL; MYOFIBROBLAST; OSTEOSARCOMA; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SKIN CANCER; STEM CELL NICHE; TUMOR CELL INOCULATION; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIUM; HUMAN; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

CELL DIFFERENTIATION; ENDOTHELIAL CELLS; FIBROBLASTS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84941774559     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.08.005     Document Type: Review

References (93)

1. Fuchs E., Tumbar T., Guasch G. Socializing with the neighbors: stem cells and their niche. Cell 2004, 116:769-778. (PMID: 15035980).
2. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C., Jones D.L., Visvader J., Weissman I.L., Wahl D.L. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344. (PMID: 16990346).
3. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 2012, 12:133-143. (PMID: 22237392). 10.1038/nrc3184.
4. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., R.A.Weinberg RA An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 2008, 40:499-507. (PMID: 18443585). 10.1038/ng.127.
5. Wong D.J., Liu H., Ridky T.W., Cassarino D., Segal E., H.Y.Chang HY Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2:333-344. (PMID: 18397753). 10.1016/j.stem.2008.02.009.
6. Somervaille T.C., Matheny C.J., Spencer G.J., Iwasaki M., Rinn J.L., Witten D.M., Chang H.Y., Shurtleff S.A., Downing J.R., M.L.Cleary ML Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 2009, 4:129-140. (PMID: 19200802). 10.1016/j.stem.2008.11.015.
7. Voog J., Jones D.J. Stem cells and the niche: a dynamic duo. Cell Stem Cell 2010, 6:103-115. (PMID: 20144784). 10.1016/j.stem.2010.01.011.
8. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14:275-291. (PMID: 24607403). 10.1016/j.stem.2014.02.006.
9. Takakura N., Huang X.L., Naruse T., Hamaguchi I., Dumont D.J., Yancopoulos G.D., Suda T. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity 1998, 9:677-686. (PMID: 9846489).
10. Ottersbach K., Dzierzak E. The murine placenta contains hematopoietic stem cells within the vascular labyrinth region. Dev. Cell 2005, 8:377-387. (PMID: 15737933).
11. Zhang J., Niu C., Ye L., Huang H., He X., Tong W.G., Ross J., Haug J., Johnson T., Feng J.Q., Harris S., Wiedemann L.M., Mishina Y., Li L. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425:836-841. (PMID: 14574412).
12. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., Martin R.P., Schipani E., Divieti P., Bringhurst F.R., Milner L.A., Kronenberg H.M., D.T.Scadden DT Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846. (PMID: 14574413).
13. Arai F., Hirao A., Ohmura M., Sato H., Matsuoka S., Takubo K., Ito K., Koh G.Y., Suda T. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004, 118:149-161. (PMID: 15260986).
14. Kiel M.J., Radice G.L., Morrison S.J. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell 2007, 16:204-217. (PMID: 18371351). 10.1016/j.stem.2007.06.001.
15. Kiel M.J., Acar M., Radice G.L., Morrison S.J. Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance. Cell Stem Cell 2009, 4:170-179. (PMID: 19119091). 10.1016/j.stem.2008.10.005.
16. Greenbaum A.M., Revollo L.D., Woloszynek J.R., Civitelli R., Link D.C. N-cadherin in osteolineage cells is not required for maintenance of hematopoietic stem cells. Blood 2012, 120:295-302. (PMID: 22323481). 10.1182/blood-2011-09-377457.
17. Bromberg O., Frisch B.J., Weber J.M., Porter R.L., Civitelli R., Calvi L.M. Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells. Blood 2012, 120:303-313. (PMID: 22596259). 10.1182/blood-2011-09-377853.
18. Sugiyama T., Kohara H., Noda M., Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25:977-988. (PMID: 17174120).
19. Kiel M.J., Yilmaz O.H., Iwashita T., Yilmaz O.H., Terhorst C., S.J.Morrison SJ SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005, 121:1109-1121. (PMID: 15989959).
20. Sugimura R., He X.C., Venkatraman A., Arai F., Box A., Semerad C., Haug J.S., Peng L., Zhong X.B., Suda T., Li L. Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche. Cell 2012, 150:351-365. (PMID: 22817897). 10.1016/j.cell.2012.05.041.
21. Yamazaki S., Ema H., Karlsson G., Yamaguchi T., Miyoshi H., Shioda S., Taketo M.M., Karlsson S., Iwama A., Nakauchi H. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 2011, 147:1146-1158. (PMID: 22118468). 10.1016/j.cell.2011.09.053.
22. Shen Q., Goderie S.K., Jin L., Karanth N., Sun Y., Abramova N., Vincent P., Pumiglia K., Temple S. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 2004, 304:1338-1340. (PMID: 15060285).
23. Weller M., van den Bent M., Hopkins K., Tonn J.C., Stupp R., Falini A., Cohen-Jonathan-Moyal E., Frappaz D., Henriksson R., Balana C., Chinot O., Ram Z., Reifenberger G., Soffietti R., Wick W., European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014, 15:e395-e403. (PMID: 25079102). 10.1016/S1470-2045(14)70011-7.
24. Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Bonnefoi H., Cameron D., Gianni L., Valagussa P., Swain S.M., Prowell T., Loibl S., Wickerham D.L., Bogaerts J., Baselga J., Perou C., Blumenthal G., Blohmer J., Mamounas E.P., Bergh J., Semiglazov V., Justice R., Eidtmann H., Paik S., Piccart M., Sridhara R., Fasching P.A., Slaets L., Tang S., Gerber B., Geyer C.E., Pazdur R., Ditsch N., Rastogi P., Eiermann W., von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014, 384:164-172. (PMID: 24529560). 10.1016/S0140-6736(13)62422-8.
25. Purow B., Schiff D. Advances in the genetics of glioblastoma: are we reaching critical mass?. Nat. Rev. Neurol. 2009, 5:419-426. (PMID: 19597514). 10.1038/nrneurol.2009.96.
26. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401. (PMID: 15549107).
27. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15178-15183. (PMID: 14645703).
28. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526. (PMID: 22854781). 10.1038/nature11287.
29. Flavahan W.A., Wu Q., Hitomi M., Rahim N., Kim Y., Sloan A.E., Weil R.J., Nakano I., Sarkaria J.N., Stringer B.W., Day B.W., Li M., Lathia J.D., Rich J.N., Hjelmeland A.B. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat. Neurosci. 2013, 16:1373-1382. (PMID: 23995067). 10.1038/nn.3510.
30. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., Frank A., Bayazitov I.T., Zakharenko S.S., Gajjar A., Davidoff A., R.J.Gilbertson RJ A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82. (PMID: 17222791).
31. Ikushima H., Todo T., Ino Y., Takahashi M., Miyazawa K., Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009, 5:504-514. (PMID: 19896441). 10.1016/j.stem.2009.08.018.
32. Bhat K.P., Balasubramaniyan V., Vaillant B., Ezhilarasan R., Hummelink K., Hollingsworth F., Wani K., Heathcock L., James J.D., Goodman L.D., Conroy S., Long L., Lelic N., Wang S., Gumin J., Raj D., Kodama Y., Raghunathan A., Olar A., Joshi K., Pelloski C.E., Heimberger A., Kim S.H., Cahill D.P., Rao G., Den Dunnen W.F., Boddeke H.W., Phillips H.S., Nakano I., Lang F.F., Colman H., Sulman E.P., Aldape K. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 2013, 24:331-346. (PMID: 23993863). 10.1016/j.ccr.2013.08.001.
33. Mao P., Joshi K., Li J., Kim S.H., Li P., Santana-Santos L., Luthra S., Chandran U.R., Benos P.V., Smith L., Wang M., Hu B., Cheng S.Y., Sobol R.W., Nakano I. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:8644-8649. (PMID: 23650391). 10.1073/pnas.1221478110.
34. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K.E., Geber A., Fligelman B., Leversha M., Brennan C., Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833. (PMID: 21102433). 10.1038/nature09624.
35. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., Maira G., Parati E.A., Stassi G., Larocca L.M., De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828. (PMID: 21102434). 10.1038/nature09557.
36. Beck B., Driessens G., Goossens S., Youssef K.K., Kuchnio A., Caauwe A., Sotiropoulou P.A., Loges S., Lapouge G., Candi A., Mascre G., Drogat B., Dekoninck S., Haigh J.I., Carmeliet P., Blanpain C. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478:399-403. (PMID: 22012397). 10.1038/nature10525.
37. Barker N., Huch M., Kujala P., van de Wetering M., Snippert H.J., van Es J.H., Sato T., Stange D.E., Begthel H., van den Born M., Danenberg E., van den Brink S., Korving J., Abo A., Peters P.J., Wright N., Poulsom R., Clevers H. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 2010, 6:25-36. (PMID: 20085740). 10.1016/j.stem.2009.11.013.
38. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480. (PMID: 17081971).
39. Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L.A., Knuechel R., Kirchner T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10356-10361. (PMID: 11526241).
40. Dow L.E., O'Rourke K.P., Simon J., Tschaharganeh D.F., van Es J.H., Clevers H., S.W.Lowe SW Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 2015, 161:1539-1552. 10.1016/j.cell.2015.05.033.
41. Loeffler M., Krüger J.A., Niethammer A.G., R.A.Reisfeld RA Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 2006, 116:1955-1962. (PMID: 16794736).
42. Vermeulen L., De Sousa E., Melo F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., Tuynman J.B., Todaro M., Merz C., Rodermond H., Sprick M.R., Kemper K., Richel D.J., Stassi G., Medema J.P. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12:468-476. (PMID: 20418870). 10.1038/ncb2048.
43. Quante M., Tu S.P., Tomita H., Gonda T., Wang S.S., Takashi S., Baik G.H., Shibata W., Diprete B., Betz K.S., Friedman R., Varro A., Tycko B., Wang T.C. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011, 19:257-272. (PMID: 21316604). 10.1016/j.ccr.2011.01.020.
44. Lu J., Ye X., Fan F.F., Xia L., Bhattacharya R., Bellister S., Tozzi F., Sceusi E., Zhou Y., Tachibana I., Maru D.M., Hawke D.H., Rak J., Mani S.A., Zweidler-McKay P., Ellis L.M. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 2013, 23:171-185. (PMID: 23375636). 10.1016/j.ccr.2012.12.021.
45. Stephens P.J., Greenman C.D., Fu B., Yang F., Bignell G.R., Mudie L.J., Pleasance E.D., Lau K.W., Beare D., Stebbings L.A., McLaren S., Lin M.L., McBride D.J., Varela I., Nik-Zainal S., Leroy C., Jia M., Menzies A., Butler A.P., Teague J.W., Quail M.A., Burton J., Swerdlow H., Carter N.P., Morsberger L.A., Iacobuzio-Donahue C., Follows G.A., Green A.R., Flanagan A.M., Stratton M.R., Futreal P.A., Campbell P.J. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40. (PMID: 21215367). 10.1016/j.cell.2010.11.055.
46. Fei Y., Xiao L., Doetschman T., Coffin D.J., Hurley M.M. Fibroblast growth factor 2 stimulation of osteoblast differentiation and bone formation is mediated by modulation of the Wnt signaling pathway. J. Biol. Chem. 2011, 286:40575-40583. (PMID: 21987573). 10.1074/jbc.M111.274910.
47. Shimizu T., Sugihara E., Yamaguchi-Iwai S., Tamaki S., Koyama Y., Kamel W., Ueki A., Ishikawa T., Chiyoda T., Osuka S., Onishi N., Ikeda H., Kamei J., Matsuo K., Fukuchi Y., Nagai T., Toguchida J., Toyama Y., Muto A., Saya H. IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress. Cancer Res. 2014, 74:6531-6541. (PMID: 25273088). 10.1158/0008-5472.CAN-14-0914.
48. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3983-3988. (PMID: 12629218).
49. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545. (PMID: 11229684).
50. Naugler W.E., Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 2008, 18:19-26. (PMID: 18440219). 10.1016/j.gde.2008.01.020.
51. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. (PMID: 21376230). 10.1016/j.cell.2011.02.013.
52. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706. (PMID: 19878981). 10.1016/j.cell.2009.10.014.
53. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., Wicinski J., Cabaud O., Charafe-Jauffret E., Birnbaum D., Guan J.L., Dontu G., Wicha M.S. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 2010, 120:485-497. (PMID: 20051626). 10.1172/JCI39397.
54. Boelens M.C., Wu T.J., Nabet B.Y., Xu B., Qiu Y., Yoon T., Azzam D.J., Twyman-Saint Victor C., Wiemann B.Z., Ishwaran H., Ter Brugge P.J., Jonkers J., Slingerland J., Minn A.J. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 2014, 159:499-513. (PMID: 25417103). 10.1016/j.cell.2014.09.051.
55. Yamamoto M., Taguchi Y., Ito-Kureha T., Semba K., Yamaguchi N., Inoue J. NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat. Commun. 2013, 4:2299. (PMID: 23934482). 10.1038/ncomms3299.
56. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648. (PMID: 7509044).
57. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
58. Kikushige Y., Shima T., Takayanagi S., Urata S., Miyamoto T., Iwasaki H., Takenaka K., Teshima T., Tanaka T., Inagaki Y., Akashi K. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010, 7:708-717. (PMID: 9212098).
59. Aikawa Y., Katsumoto T., Zhang P., Shima H., Shino M., Terui K., Ito E., Ohno H., Stanley E.R., Singh H., Tenen D.G., Kitabayashi I. PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2. Nat. Med. 2010, 16:580-585. (PMID: 20418886). 10.1038/nm.2122.
60. Naka K., Hoshii T., Muraguchi T., Tadokoro Y., Ooshio T., Kondo Y., Nakao S., Motoyama N., Hirao A. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010, 463:676-680. (PMID: 20130650). 10.1038/nature08734.
61. Zhao M., Perry J.M., Marshall H., Venkatraman A., Qian P., He X.C., Ahamed J., Li L. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat. Med. 2014, 20:1321-1326. (PMID: 25326798). 10.1038/nm.3706.
62. Bruns I., Lucas D., Pinho S., Ahmed J., Lambert M.P., Kunisaki Y., Scheiermann C., Schiff L., Poncz M., Bergman A., Frenette P.S. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat. Med. 2014, 20:1315-1320. (PMID: 25326802). 10.1038/nm.3707.
63. Kobayashi C.I., Takubo K., Kobayashi H., Nakamura-Ishizu A., Honda H., Kataoka K., Kumano K., Akiyama H., Sudo T., Kurokawa M., Suda T. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Blood 2014, 123:2540-2549. (PMID: 24574458). 10.1182/blood-2013-07-517847.
64. Iriuchishima H., Takubo K., Miyakawa Y., Nakamura-Ishizu A., Miyauchi Y., Fujita N., Miyamoto K., Miyamoto T., Ikeda E., Kizaki M., Nojima Y., Suda T. Neovascular niche for human myeloma cells in immunodeficient mouse bone. PLoS ONE 2012, 7:e30557. (PMID: 22347385). 10.1371/journal.pone.0030557.
65. Oskarsson T., Batlle E., Massagué J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 2014, 14:306-321. (PMID: 24607405). 10.1016/j.stem.2014.02.002.
66. Ueno M., Itoh M., Kong L., Sugihara K., Asano M., Takakura N. PSF1 is essential for early embryogenesis in mice. Mol. Cell. Biol. 2005, 25:10528-10532. (PMID: 16287864).
67. Ueno M., Itoh M., Sugihara K., Asano M., Takakura M.N. Both alleles of PSF1 are required for maintenance of pool size of immature hematopoietic cells and acute bone marrow regeneration. Blood 2009, 113:555-562. (PMID: 18984863). 10.1182/blood-2008-01-136879.
68. Kong L., Ueno M., Itoh M., Yoshioka K., Takakura N. Identification and characterization of mouse PSF1-binding protein, SLD5. Biochem. Biophys. Res. Commun. 2006, 339:1204-1207. (PMID: 16338220).
69. Mohri T., Ueno M., Nagahama Y., Gong Z.Y., Asano M., Oshima H., Oshima M., Fujio Y., Takakura N. Requirement of SLD5 for early embryogenesis. PLoS ONE 2013, 8. (PMID: 24244394). 10.1371/journal.pone.0078961. eCollection 2013.
70. Assou S., Le Carrour T., Tondeur S., Ström S., Gabelle A., Marty S., Nadal L., Pantesco V., Réme T., Hugnot J.P., Gasca S., Hovatta O., Hamamah S., Klein B., De Vos J. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells 2007, 25:961-973. (PMID: 17204602).
71. Tahara H., Naito H., Kise K., Wakabayashi T., Kamoi K., Okihara K., Yanagisawa A., Nakai Y., Nonomura N., Morii E., Miki T., Takakura T. Evaluation of PSF1 as a prognostic biomarker for prostate cancer. Prostate Cancer Prostatic Dis. 2015, 18:56-62. (PMID: 25403418). 10.1038/pcan.2014.46.
72. Nagahama Y., Ueno M., Miyamoto S., Morii E., Minami T., Mochizuki N., Saya H., Takakura N. PSF1, a DNA replication factor expressed widely in stem and progenitor cells, drives tumorigenic and metastatic properties. Cancer Res. 2010, 70:1215-1224. (PMID: 20103637). 10.1158/0008-5472.CAN-09-3662.
73. Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm. Res. 2008, 25:500-511. (PMID: 17896100).
74. Motz G.T., Santoro S.P., Wang L.P., Garrabrant T., Lastra R.R., Hagemann I.S., Lal P., Feldman M.D., Benencia F., Coukos G. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 2014, 20:607-615. (PMID: 24793239). 10.1038/nm.3541.
75. Voron T., Colussi O., Marcheteau E., Pernot S., Nizard M., Pointet A.L., Latreche S., Bergaya S., Benhamouda N., Tanchot C., Stockmann C., Combe P., Berger A., Zinzindohoue F., Yagita H., Tartour E., Taieb J., Terme M. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 2015, 212:139-148. (PMID: 25601652). 10.1084/jem.20140559.
76. Ebos J.N., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 2011, 8:210-221. (PMID: 21364524). 10.1038/nrclinonc.2011.21.
77. Rosen L.S. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005, 10:382-391. (PMID: 15967832).
78. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62. (PMID: 15637262).
79. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427. (PMID: 21629292). 10.1038/nrd3455.
80. Jain R.K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014, 26:605-622. (PMID: 25517747). 10.1016/j.ccell.2014.10.006.
81. Ding B.S., Nolan D.J., Butler J.M., James D., Babazadeh A.O., Rosenwaks Z., Mittal V., Kobayashi H., Shido K., Lyden D., Sato T.N., Rabbany S.Y., Rafii S. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 2010, 468:310-315. (PMID: 21068842). 10.1038/nature09493.
82. Cooke V.G., LeBleu V.S., Keskin D., Khan Z., O'Connell J.T., Teng Y., Duncan M.B., Xie L., Maeda G., Vong S., Sugimoto H., Rocha R.M., Damascena A., Brentani R.R., Kalluri R. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012, 21:66-81. (PMID: 22264789). 10.1016/j.ccr.2011.11.024.
83. Matsui T., Kinugasa Y., Tahara H., Kanakura Y., Takakura N. Possible role of mural cell covered mature blood vessels in inducing drug resistance in cancer-initiating cells. Am. J. Pathol. 2013, 182:1790-1799. (PMID: 23473746). 10.1016/j.ajpath.2013.01.019.
84. Kinugasa Y., Matsui T., Takakura N. CD44 expressed on CAFs is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells 2014, 32:145-156. (PMID: 24395741). 10.1002/stem.1556.
85. Ghesquière B., Wong B.W., Kuchnio A., Carmeliet P. Metabolism of stromal and immune cells in health and disease. Nature 2014, 511:167-176. (PMID: 25008522). 10.1038/nature13312.
86. Jinushi M., Chiba S., Yoshiyama H., Masutomi K., Kinoshita I., Dosaka-Akita H., Yagita H., Takaoka A., Tahara H. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12425-12430. (PMID: 21746895). 10.1073/pnas.1106645108.
87. Mitchem J.B., Brennan D.J., Knolhoff B.L., Belt B.A., Zhu Y., Sanford D.E., Belaygorod L., Carpenter D., Collins L., Piwnica-Worms D., Hewitt S., Udupi G.M., Gallagher W.M., Wegner C., West B.L., Wang-Gillam A., Goedegebuure P., Linehan D.C., DeNardo D.G. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013, 73:1128-1141. (PMID: 23221383). 10.1158/0008-5472.CAN-12-2731.
88. Yang J., Liao D., Chen C., Liu Y., Chuang T.H., Xiang R., Markowitz D., Reisfeld R.A., Luo Y. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 2013, 31:248-258. (PMID: 23169551). 10.1002/stem.1281.
89. Panni R.Z., Sanford D.E., Belt B.A., Mitchem J.B., Worley L.A., Goetz B.D., Mukherjee P., Wang-Gillam A., Link D.C., Denardo D.G., Goedegebuure S.P., Linehan D.C. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunol. Immunother. 2014, 63:513-528. (PMID: 24652403). 10.1007/s00262-014-1527-x.
90. Bayne L.J., Beatty G.L., Jhala N., Clark C.E., Rhim A.D., Stanger B.Z., Vonderheide R.H. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012, 21:822-835. (PMID: 22698406). 10.1016/j.ccr.2012.04.025.
91. Cui T.X., Kryczek I., Zhao L., Zhao E., Kuick R., Roh M.H., Vatan L., Szeliga W., Mao Y., Thomas D.G., Kotarski J., Tarkowski R., Wicha M., Cho K., Giordano T., Liu R., Zou W. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 2013, 39:611-621. (PMID: 24012420). 10.1016/j.immuni.2013.08.025.
92. Korkaya H., Kim G.I., Davis A., Malik F., Henry N.L., Ithimakin S., Quraishi A.A., Tawakkol N., D'Angelo R., Paulson A.K., Chung S., Luther T., Paholak H.J., Liu S., Hassan K.A., Zen Q., Clouthier S.G., Wicha M.S. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 2012, 47:570-584. (PMID: 22819326). 10.1016/j.molcel.2012.06.014.
93. Putoczki T.L., Thiem S., Loving A., Busuttil R.A., Wilson N.J., Ziegler P.K., Nguyen P.M., Preaudet A., Farid R., Edwards K.M., Boglev Y., Luwor R.B., Jarnicki A., Horst D., Boussioutas A., Heath J.K., Sieber O.M., Pleines I., Kile B.T., Nash A., Greten F.R., McKenzie B.S., Ernst M. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 2013, 24:257-271. (PMID: 23948300). 10.1016/j.ccr.2013.06.017.